AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 3 - (NewsRx.com & NewsRx.net) -- Genencor International, Inc., (GCOR) will begin phase I safety and immunogenicity testing for its DNA-based therapeutic vaccine to treat hepatitis B.
Trials are scheduled to begin under an investigational new drug application (IND) filed by Genencor in December 2003.
Epimmune, Inc., collaborated on the design and preclinical development of the vaccine under its collaboration agreement with Genencor and will receive a milestone payment as a result of the IND filing.
"This first IND for Genencor represents important progress in our healthcare business," said Mark A. Goldsmith, MD, PhD, Genencor's senior vice president, healthcare.
He continued: "In less than 3 years, we've shown that we can ...